Recipient of federal assistance · GREER, SC

NUBAD LLC

NUBAD LLC received -$144 in federal grants and other assistance in FY2026, on 5 actions. It has no federal contracts in the loaded years. Since FY2021: $11.4M.

Assistance · FY2026
-$144
New awards
0
Actions
5
Since FY2021
$11.4M
UEI
ENA5G1N2MWP4
Location
GREER, SC
Businesses
Open in the explorerFederal grants & assistance

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

Assistance by fiscal year

  1. 2.9MFY2021
  2. 1.8MFY2022
  3. 3.5MFY2023
  4. 3.2MFY2024
  5. 0FY2025
  6. -143.8FY2026

By type

  1. Grants-$1440.0%

Top programs · Awarding agencies

Obligations in FY2026.

Top programs

  1. 93.855 · Allergy and Infectious Diseases Research-$1440.0%

Largest awards

  1. DEVELOPMENT OF PEPTIDE NUCLEIC ACID ANTIBIOTICS - THE WORLD IS RAPIDLY HEADING TOWARDS A PRE-1940’S SCENARIO WHEN IT COMES TO FIGHTING…$3.2M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Feb 8, 2021 – May 6, 2026· R42AI114114
  2. AMINOGLYCOSIDES WITH REDUCED OTOTOXICITY - PROJECT SUMMARY AMINOGLYCOSIDES ARE ONE OF THE CHEAPEST AND WELL-KNOWN ANTIBIOTICS IN CLINICAL…$3M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Mar 24, 2021 – Jun 30, 2026· R42AI126874
  3. OTOTOXICITY OF MODIFIED AMINOGLYCOSIDES - PROJECT SUMMARY AMINOGLYCOSIDES ARE ONE OF THE CHEAPEST AND WELL-KNOWN ANTIBIOTICS IN CLINICAL…$3M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Jul 11, 2022 – Jun 30, 2026· R44AI172739
  4. A BIOPHYSICAL ASSAY TARGETING SARS COV-2 RNA - PROJECT SUMMARY THE WORLD IS IMMERSED IN A HEALTH CRISIS RIVALED ONLY BY THE SPANISH FLU…$598.6K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Jun 27, 2022 – Aug 20, 2026· R43AI167095
  5. A BIOPHYSICAL ASSAY TARGETING GYRASE RNA - PROJECT SUMMARY THE WORLD IS RAPIDLY HEADING TOWARDS A PRE-1940’S SCENARIO WHEN IT COMES TO…$521K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Apr 11, 2022 – May 19, 2026· R43AI170191

Subawards

Matched by Unique Entity ID: the first-tier subawards this organization reported as a prime recipient, and those primes reported paying it.

As a prime: who it pays · FY2026

No subawards reported as a prime in FY2026.

As a sub-recipient: who pays it · FY2026

No subawards reported to it in FY2026.

By fiscal year

  • FY2021: $774.6K paid out · $0 received
  • FY2023: $749.3K paid out · $0 received
  • FY2024: $749.3K paid out · $0 received

Primes report first-tier subawards of $30,000 or more themselves, and many go unreported (GAO-24-106214). Reporting moved from FSRS to SAM.gov in March 2025 and fewer sub-contracts have been reported since. Amounts are what primes reported; they are never added to prime award totals.

Source: Subawards (first-tier sub-contracts and sub-grants reported under FFATA) (U.S. Department of the Treasury, USAspending.gov (reports filed in SAM.gov, formerly FSRS)), data current to Oct 7, 2026, loaded Oct 7, 2026 · Subawards loaded from FY2021.

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 7, 2026, loaded Oct 7, 2026 · FY2021–FY2026.